176 related articles for article (PubMed ID: 29223373)
1. Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis.
Yeh JC; Shank BR; Milton DR; Qazilbash MH
Biol Blood Marrow Transplant; 2018 Apr; 24(4):815-819. PubMed ID: 29223373
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.
Lisenko K; Wuchter P; Hansberg M; Mangatter A; Benner A; Ho AD; Goldschmidt H; Hegenbart U; Schönland S
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1870-1878. PubMed ID: 28754546
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
4. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
6. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
[TBL] [Abstract][Full Text] [Related]
7. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.
Gettys SC; Gulbis A; Wilhelm K; Sasaki K; Dinh Y; Rondon G; Qazilbash MH
Eur J Haematol; 2017 Apr; 98(4):388-392. PubMed ID: 28009447
[TBL] [Abstract][Full Text] [Related]
8. Poor mobilization of autologous CD34
Gifford G; Hesson L; Wong JWH; Carroll A; Gabrielli S; Bai L; Xia W; Stevenson W; Greenwood M
Br J Haematol; 2021 May; 193(4):841-844. PubMed ID: 33481245
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
[TBL] [Abstract][Full Text] [Related]
10. Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease.
Blank N; Lisenko K; Pavel P; Bruckner T; Ho AD; Wuchter P
Eur J Haematol; 2016 Jul; 97(1):78-82. PubMed ID: 26381040
[TBL] [Abstract][Full Text] [Related]
11. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
Kamezaki K; Kikushige Y; Numata A; Miyamoto T; Takase K; Henzan H; Aoki K; Kato K; Nonami A; Kamimura T; Arima F; Takenaka K; Harada N; Fukuda T; Hayashi S; Ohno Y; Eto T; Harada M; Nagafuji K
Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
[TBL] [Abstract][Full Text] [Related]
12. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis.
Badar T; Khan MA; Szabo A; Drobyski W; Chhabra S; Dhakal B; Fenske TS; Hamadani M; Hari P; Jerkins JH; Shah NN; Shaw BE; D'Souza A
Amyloid; 2019 Dec; 26(4):210-215. PubMed ID: 31347424
[TBL] [Abstract][Full Text] [Related]
13. Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis.
Rodríguez-Lobato LG; Fernández de Larrea C; Cibeira MT; Tovar N; Aróstegui JI; Rosiñol L; Díaz T; Lozano E; Elena M; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1269-1275. PubMed ID: 28434927
[TBL] [Abstract][Full Text] [Related]
14. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.
Leung N; Leung TR; Cha SS; Dispenzieri A; Lacy MQ; Gertz MA
Blood; 2005 Nov; 106(10):3353-7. PubMed ID: 16037390
[TBL] [Abstract][Full Text] [Related]
15. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
16. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Abdallah AA; Alapat D; Kaur V; Atrash S
J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma EPO and MIP-1 alpha are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts.
Labonté L; Li Y; Yang L; Gillingham A; Halpenny M; Giulivi A; Sills T; Evans K; Zanke B; Allan DS
Exp Hematol; 2009 Jun; 37(6):673-8. PubMed ID: 19463769
[TBL] [Abstract][Full Text] [Related]
19. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
[TBL] [Abstract][Full Text] [Related]
20. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.
Sharpley FA; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Fontana M; Martinez-Naharro A; Quarta C; Hawkins PN; Wechalekar AD
Br J Haematol; 2019 Dec; 187(5):642-652. PubMed ID: 31410841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
